Pharma Triple Top PatternPharma, a company engange in research and developing medical drug and devices was a darling in pharmaceutical in Malaysia.
Recently, it had been hit hard with expired vaccine and the obsolete of PPE, needles etc (for Covid 19 use) impairment which was not utilised by the MOF.
The recovery of its share price had been distorted as they are facing some dispute issue with MOF regarding ventiltor urgent supply which was claimed as malfunction.
On chart pattern wise, a triple top pattern had been formed which is a bearish signal. The RSI is also showing the reading at 70.97% which can be consider near to overbought. But if it could close above 0.450 before it retouch 0.370 than the triple top pattern will be cancelled out.
In summary,
1) if it cannot break and close at 0.450 or above, the triple top pattern play out. It may drop to TP1: 0.350, TP2: 0.325
2) if it close at 0.450 or above, the bearish pattern shall be cancel. It may rally to 0.515 to close gap.
Disclaimer:
This is not a Buy / Sell call. This material is for learning purposes only.
Consult your financial advisor and trade at your own risk.
PHARMA trade ideas
Pharma, catching my attentionAfter 2 weeks of rebounding from the bottom, it has come to the weekly trendline resistance at 0.425sen. Obviously it is not the right timing to enter as it will retrace anytime from the resistance line.
Hence, the surge of price does not supported with volume. I will wait for the higher low form above this resistance line before making any consideration. That will be probably around April24.
Feel free to leave your comment and give me a LIKES for your support.
Pharma - end of mid term swing?Overall it's a purebear stock with mid term swing.
Price was dropped 10% from 470.
Currently still stay above EMA7 (yellow area).
Might drop to EMA20 or below.
Operator must slowly distribute. Watch out folks.
Disclaimer: Mentioned stocks are solely based on own opinions for education and/or discussion purpose only. There's no buy and/or sell recommendation. Trading involve financial risk on your own. The author shall not be responsible for any losses or lost profits resulting from investment decisions based on the use of the information contained herein.
Pharmaniaga - TP at 6 range possible?MYX:PHARMA
With recent business deal signings will the punters back to this counter?
From 2-3 days observation, personally this counter may still overlooked with addition of MCO 2.0 being introduced - the volume is just not there (yet?)
Like it or not 14mils doses has been bought even some may decries the subpar 50%++ effective rate of Sinovac covid19 vaccine that being shared by certain country.
The stock best performance was recorded last Aug, where the price hit 6.69 which is a handsome multiplier of the price prior to covid era averaging ~2 in last Jan-Feb
*This is not a call sign - the writer can't confirm or deny any dealings related to this stock
Vaccine Counter PHARMA Downtrend SignsSupposedly the beneficiary of the vaccine story as one of the appointees approved by the government. A duopoly with DPHARMA. However... their price & volume action is dimming fast..
The cup and handle pattern is invalidated.
The recent decision to prioritize Pfizer vaccine over Sinovac really trigger a sell-down on PHARMA stock price with high volume. Expect continued selling in the coming days.
www.straitstimes.com
The rest of the vaccine related stock hype: Kanger, Solution, HWGB, Yongtai, Bintai , yet to see any new development as the government controlled tightly the distribution and sale of vaccine to the public from third parties.
Disclaimer
This information only serves as reference information and does not constitute a buy or sell call. Conduct your own research and assessment before deciding to buy or sell any stock
Analysis on Pharmaniaga Performance in a Bullish TrendTP: RM 7.20
Comments:
Expected to peak at RM7 by 1st week of August.
statement rationale:
1. Pharmaniaga has been on a downtrend trajectory since May 2015 and has formed a reversal pattern, (cup & handle in daily and weekly chart)
2. Strong product demand, expecting vaccination peak Q3 & Q4/2021. with the arrival of Sinovac Vaccine in July 2021, Pharma share price is expected to beat analyst expectation of RM5.20.
3. Current increase has been supported by AstraZaneca vaccination programme (as at 27 May 2021)
Expecting bullish run until Q1 - Q2/2022 based on past bullish performance between May 2009 - April 2015. which lasted for 217 days, about 7 months bullish run.
The potential to break RM7.3 (alltime high, Apr 2015) will depend on the demand and supply of the global vaccination provider. The vaccination industry is expecting to decline due to the risk mentioned below:
1. More vaccine provider will emerge hence increase the level of competition
2. Higher production cost
3. The cases of covid-19 in malaysia, or the effectivity of vaccine.
4. Global vaccination supply and demand (supply chain)
5. Financial performance
Disclaimer: This analysis is based on the technical analysis backed by some of the sentiment that influencing the price movement,
NOT A BUY CALL :)
Catching up ATHPharmaniaga is Bullish and could be catching up ATH price at 7.35 after breaking above symmetrical triangle coincides MACD buy signal above zero level. The share could potentially reach 10.0 if it could close above 7.35 along the trading week. Exit the trade if the price close below 5.0 along the week.
Disclaimer: The content on this analysis is subject to change at any time without notice, and is provided for the sole purpose of assisting traders to make independent investment decisions.
PHARMA (30/11/2020) consolidating in ascending triangleIn H4, the stock is forming price action in ascending triangle pattern. Currently is consolidating between 5.42 and 5.80. A good entry would be after it breakout from the triangle @ EP 5.86 with Support at 5.38. TP is at 6.73 and new 52WH 8.25 (Fibo 1.272) - RRR 1:1.8
EP 5.86
TP 6.73 / 8.25
SL 5.38
Stochastic shows a pullback signal, MACD didn’t signal any breakout, and RSI didn’t show any good momentum for entry now.
PHARMA is one of market leader in Pharmaceutical sector with competitive balanced float (21% of 1440M shares) compared to its sector competitor AHEALTH (23% of 1780M shares). However, current vaccine sentiment will definitely help PHARMA in the long run.
TAYOR